Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV

AIDS

Volumn 12, Issue 3, 1998, Pages 301-308

  Simonds, R J ^a   Steketee, Richard ^a   Nesheim, Steven ^b   Matheson, Pamela ^c   Palumbo, Paul ^d   Alger, Lindsay ^e   Abrams, Elaine J ^c   Orloff, Sherry ^a   Lindsay, Michael ^b   Bardeguez, Arlene D ^d   Vink, Peter ^e   Byers, Robert ^a   Rogers, Martha ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY   (United States)

^c New York City Perinatal HIV T   (United States)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

Author keywords

Antiviral therapy; Epidemiology; Obstetrics gynecology; Pediatrics; Risk factors; Vertical transmission

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; ZIDOVUDINE;

ARTICLE; BIRTH WEIGHT; CLINICAL TRIAL; COHORT ANALYSIS; CONGENITAL INFECTION; DRUG EFFICACY; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NEWBORN; PERINATAL INFECTION; PREMATURE FETUS MEMBRANE RUPTURE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREVALENCE; RISK; RISK FACTORS; ZIDOVUDINE;

EID: 6844252916     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199803000-00008     Document Type: Article

References (34)

1. Mofenson LM: Epidemiology and determinants of vertical HIV transmission. Semin Pediatr Infect Dis 1994, 5:252-265.
2. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994, 331:1173-1180.
3. Centers for Disease Control and Prevention: Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994, 43 (RR-11):1-20.
4. American College of Obstetricians and Gynecologists Committee on Obstetric Practice: Zidovudine for the Prevention of Vertical Transmission of Human Immunodeficiency Virus. American College of Obstetricians and Gynecologists Committee Opinion 148, Washington, DC: American College of Obstetricians and Gynecologists; December 1994.
5. Fiscus SA, Adimora AA, Schoenbach VJ, et al.: Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA 1996, 275:1483-1488.
6. Cooper ER, Nugent RP, Diaz C, et al.: After AIDS Clinical Trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis 1996, 174:1207-1211.
7. Blanche S, Mayaux MJ, Mandelbrot L, et al.: Acceptability and impact of zidovudine prevention on mother to child HIV-1 transmission in France. Fourth Conference on Retroviruses and Oppurtunistic Infections. Washington, DC, January 1997.
8. Landesman SH, kalish LA, Burns DN et al.: Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med 1996, 334:1617-1623.
9. Minkoff H, Monfenson LM: The role of obstetric interventions in the prevention of pediatric human immunodeficiency virus infection. Am J Obstet Gynecol 1994, 171:1167-1175.
10. Landers DV, Sweet RL: Reducing mother-to-infanl transmission of HIV: the door remains open. N Engl J Med 1996, 334:1664-1665.
11. Thomas PA, Weedon J, Krasinski K, et al.: Maternal predictors of perinatal HIV transmission. Pediatr Infect Dis J 1994, 13:489-495.
12. Mayers MM, Davenny K, Schoenbaum EE, et al.: A prospective study of infants of human immunodeficiency virus seropositive and seronegative women with a history of intravenous drug use or of intravenous drug-using sex partners, in the Bronx, New York City. Pediatrics 1991, 88:1248-1256.
13. Nesheim SR, Lindsay M, Sawyer MK, et al.: A prospective population-based study of HIV perinatal transmission. AIDS 1994, 8:1293-1298.
14. Nair P, Alger L, Hines S, Seiden S, Hebel R, Johnson JP: Maternal and neonatal characteristics associated with HIV infection in infants of seropositive women. J Acquir Immune Defic Syndr 1993, 6:298-302.
15. Abrams EJ, Matheson PB, Thomas PA, et al.: Neonatal predictors of infection status and early death among 332 infants at risk of HIV-1 infection monitored prospectively from birth. Pediatrics 1995, 96:451-458.
16. Matheson PB, Weedon J, Cappelli M, et al.: Comparison of methods of estimating the mother-to-child transmission rate of human immunodeficiency virus type 1 (HIV-1). Am J Epidemiol 1995, 142:714-718.
17. Matheson PB, Abrams EJ, Thomas PA, et al.: Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. J Infect Dis 1995, 172:353-358.
18. Centers for Disease Control: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR, 1992, 41 (RR-17):1-19.
19. Burns DN, Landesman S, Muenz LR, et al.: Cigarette smoking, premature rupture of membranes, and vertical transmission of HIV-1 among women with low CD4+ levels. J Acquir Immune Defic Syndr 1994, 7:718-726.
20. Dean AG, Dean JA, Coulombier D, et al.: Lpi Info, Version 6: A Word Processing, Database, and Statistics Program for Public Health on IBM-Compatible Microcomputers. Atlanta: Centers for Disease Control and Prevention; 1995.
21. Dixon WJ (Ed): BMDP Statistical Software Manual, 1990 Release. Los Angeles: BMDP Statistical Software, Inc.; 1990.
22. Northridge ME: Annotation: public health methods: attributable risk as a link between causality and public health action. Am J Public Health 1995, 85:1202-1204.
23. Orloff SL, Vink P, Nesheim S, et al.: Perinatal zidovudine use after perinatal ZDV recommendations in the United States. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeC3584].
24. Centers for Disease Control and Prevention: AIDS among children: United States, 1996. MMWR 1996, 45:1005-1010.
25. European Collaborative Study Group: Risk factors for mother-to-child transmission of HIV-1. Lancet 1992, 339:1007-1012.
26. St Louis ME, kamenga M, Brown C, et al.: Risk for perinatal HIV-1 transmission according to maternal immunologice, virologic, and placental factors. JAMA 1993, 269:2853-2859.
27. Mandelbrot L, Mayaux MJ, Bongain A, et al.: Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. Am J Obstet Gynecol 1996, 175:661-667.
28. Sperling RS, Shapiro DE, Coombs RW, et al.: Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996, 335:1621-1629.
29. Simonds RJ, Rogers M: Preventing perinatal HIV infection: how far have we come? JAMA 1996, 275:1514-1515.
30. European Collaborative Study: Vertical transmission of HIV-1: maternal immune status and obstetric factors. AIDS 1996, 10:1675-1681.
31. Turner BJ, Mckee IJ, Silverman NS, Ha,uck WW, Fanning IR, Markson LE: Prenatal care and birth outcomes of a cohort of HIV-infected women. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 12:259-267.
32. Centers for Disease Control and Prevention: US Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR 1995, 44 (RR-7):1-15.
33. Bryson YJ: Perinatal HIV-1 transmission: recent advances and therapeutic interventions. AIDS 1996, 10 (supp; 3):S33-S42.
34. Reggy A, Simonds RJ, Rogeris M: Preventing perinatal HIV infection. AIDS 1997, 11 (suppl A):S61-S67.